The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Research Report 2025

Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Research Report 2025

Publishing Date : Mar, 2025

License Type :

Report Code : 1801521

No of Pages : 90

Ask Your Query

Report Description
Table of Content

Synopsis
Oculopharyngeal muscular dystrophy (OPMD) is a rare genetic muscle disorder with onset during adulthood most often between 40 and 60 years of age. OPMD is characterized by slowly progressive muscle disease (myopathy) affecting the muscles of the upper eyelids and the throat.
Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Oculopharyngeal Muscular Dystrophy (OPMD) Drugs market research.
Key manufacturers engaged in the Oculopharyngeal Muscular Dystrophy (OPMD) Drugs industry include Benitec Biopharma Inc., Bioblast Pharma, BioMarin, PTC Therapeutics, NS Pharma, Nobelpharma Co., Ltd, Santhera Pharmaceuticals, Pfizer Inc. and Marathon Pharmaceuticals, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Oculopharyngeal Muscular Dystrophy (OPMD) Drugs were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Oculopharyngeal Muscular Dystrophy (OPMD) Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Benitec Biopharma Inc.
Bioblast Pharma
BioMarin
PTC Therapeutics
NS Pharma
Nobelpharma Co., Ltd
Santhera Pharmaceuticals
Pfizer Inc.
Marathon Pharmaceuticals
Fibrogen
Bristol-Myers Squibb
Sarepta Therapeutics
GSK
Segment by Type
Tablets
Capsules
Injectable
Other
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Oculopharyngeal Muscular Dystrophy (OPMD) Drugs report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Index

1 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Overview
1.1 Product Overview and Scope of Oculopharyngeal Muscular Dystrophy (OPMD) Drugs
1.2 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Segment by Type
1.2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Value Comparison by Type (2023-2029)
1.2.2 Tablets
1.2.3 Capsules
1.2.4 Injectable
1.2.5 Other
1.3 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Segment by Application
1.3.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Value by Application: (2023-2029)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Size Estimates and Forecasts
1.4.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Revenue 2018-2029
1.4.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales 2018-2029
1.4.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Competition by Manufacturers
2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Average Price by Manufacturers (2018-2023)
2.4 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Oculopharyngeal Muscular Dystrophy (OPMD) Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Oculopharyngeal Muscular Dystrophy (OPMD) Drugs, Product Type & Application
2.7 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Competitive Situation and Trends
2.7.1 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Players Market Share by Revenue
2.7.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Retrospective Market Scenario by Region
3.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales by Region: 2018-2029
3.2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales by Region: 2018-2023
3.2.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales by Region: 2024-2029
3.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Revenue by Region: 2018-2029
3.3.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Revenue by Region: 2018-2023
3.3.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Revenue by Region: 2024-2029
3.4 North America Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Facts & Figures by Country
3.4.1 North America Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales by Country (2018-2029)
3.4.3 North America Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Facts & Figures by Country
3.5.1 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales by Country (2018-2029)
3.5.3 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Facts & Figures by Country
3.7.1 Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales by Country (2018-2029)
3.7.3 Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales by Type (2018-2029)
4.1.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales by Type (2018-2023)
4.1.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales by Type (2024-2029)
4.1.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales Market Share by Type (2018-2029)
4.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Revenue by Type (2018-2029)
4.2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Revenue by Type (2018-2023)
4.2.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Revenue by Type (2024-2029)
4.2.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales by Application (2018-2029)
5.1.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales by Application (2018-2023)
5.1.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales by Application (2024-2029)
5.1.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales Market Share by Application (2018-2029)
5.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Revenue by Application (2018-2029)
5.2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Revenue by Application (2018-2023)
5.2.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Revenue by Application (2024-2029)
5.2.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Benitec Biopharma Inc.
6.1.1 Benitec Biopharma Inc. Corporation Information
6.1.2 Benitec Biopharma Inc. Description and Business Overview
6.1.3 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product Portfolio
6.1.5 Benitec Biopharma Inc. Recent Developments/Updates
6.2 Bioblast Pharma
6.2.1 Bioblast Pharma Corporation Information
6.2.2 Bioblast Pharma Description and Business Overview
6.2.3 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product Portfolio
6.2.5 Bioblast Pharma Recent Developments/Updates
6.3 BioMarin
6.3.1 BioMarin Corporation Information
6.3.2 BioMarin Description and Business Overview
6.3.3 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product Portfolio
6.3.5 BioMarin Recent Developments/Updates
6.4 PTC Therapeutics
6.4.1 PTC Therapeutics Corporation Information
6.4.2 PTC Therapeutics Description and Business Overview
6.4.3 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product Portfolio
6.4.5 PTC Therapeutics Recent Developments/Updates
6.5 NS Pharma
6.5.1 NS Pharma Corporation Information
6.5.2 NS Pharma Description and Business Overview
6.5.3 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product Portfolio
6.5.5 NS Pharma Recent Developments/Updates
6.6 Nobelpharma Co., Ltd
6.6.1 Nobelpharma Co., Ltd Corporation Information
6.6.2 Nobelpharma Co., Ltd Description and Business Overview
6.6.3 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product Portfolio
6.6.5 Nobelpharma Co., Ltd Recent Developments/Updates
6.7 Santhera Pharmaceuticals
6.6.1 Santhera Pharmaceuticals Corporation Information
6.6.2 Santhera Pharmaceuticals Description and Business Overview
6.6.3 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product Portfolio
6.7.5 Santhera Pharmaceuticals Recent Developments/Updates
6.8 Pfizer Inc.
6.8.1 Pfizer Inc. Corporation Information
6.8.2 Pfizer Inc. Description and Business Overview
6.8.3 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product Portfolio
6.8.5 Pfizer Inc. Recent Developments/Updates
6.9 Marathon Pharmaceuticals
6.9.1 Marathon Pharmaceuticals Corporation Information
6.9.2 Marathon Pharmaceuticals Description and Business Overview
6.9.3 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product Portfolio
6.9.5 Marathon Pharmaceuticals Recent Developments/Updates
6.10 Fibrogen
6.10.1 Fibrogen Corporation Information
6.10.2 Fibrogen Description and Business Overview
6.10.3 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product Portfolio
6.10.5 Fibrogen Recent Developments/Updates
6.11 Bristol-Myers Squibb
6.11.1 Bristol-Myers Squibb Corporation Information
6.11.2 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Description and Business Overview
6.11.3 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product Portfolio
6.11.5 Bristol-Myers Squibb Recent Developments/Updates
6.12 Sarepta Therapeutics
6.12.1 Sarepta Therapeutics Corporation Information
6.12.2 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Description and Business Overview
6.12.3 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product Portfolio
6.12.5 Sarepta Therapeutics Recent Developments/Updates
6.13 GSK
6.13.1 GSK Corporation Information
6.13.2 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Description and Business Overview
6.13.3 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.13.4 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Product Portfolio
6.13.5 GSK Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Industry Chain Analysis
7.2 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Production Mode & Process
7.4 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales and Marketing
7.4.1 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales Channels
7.4.2 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Distributors
7.5 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Customers
8 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Dynamics
8.1 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Industry Trends
8.2 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Drivers
8.3 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Challenges
8.4 Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business:

Since 2015

Pre Sales Support:

24*7

Post Sales Support:

24*7

Turn Around Time:

Usually 2 Hours

Clients Served:

425 and counting

Clients Assisted:

1750 and counting

Client Types:

Govt Projects, Private Companies, Consultant and Individuals

Payment:

Partners with:

Number of reports:

1,000,000 and counting

Custom Research:

Available

Report Availability:

Global and Regional Reports

Report Delivery Format:

Usually PDF

Security:

Latest Life Science Market Reports

Global Support Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Global Hospital OT and X-Ray, Cathode Room Doors (Hermetically Sealed Door) Market Research Report 2025

Global Children\'s DHA Market Research Report 2025

Global Marine Derived Drugs Market Research Report 2025

Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Payments Accepted From

Connect with us at

Complete Secure Website

#socialicons>a span { top: 0px; left: -100%; -webkit-transition: all 0.3s ease; -moz-transition: all 0.3s ease-in-out; -o-transition: all 0.3s ease-in-out; -ms-transition: all 0.3s ease-in-out; transition: all 0.3s ease-in-out;} #socialicons>ahover div{left: 0px;}